0000000001310262

AUTHOR

Paola Rogliani

showing 25 related works from this author

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Corrigendum to “Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up” [Respir. Med. 153 (2019) 68–75]

2019

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDbusiness.industryHealth caremedicineIntensive care medicinebusinessmedicine.diseaseRespiratory Medicine
researchProduct

Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT)study follow-up

2019

Abstract Background Chronic obstructive pulmonary disease (COPD) is characterised by recurring exacerbations. We estimated the costs of healthcare resources for COPD management funded by the Italian National Healthcare Service (INHS) for one year. Methods We examined the demographic, clinical, and economic variables at enrolment and follow-up visits (at 6 and 12 months) of COPD patients participating in the SAT study and referred to 20 Italian pulmonary centres with different institutional characteristics. Costs were expressed in Euro (€) 2018. A random effects log-linear panel regression model was performed to predict the average cost per patient. Results Most of the centres were public in…

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyCost-Benefit AnalysisSocio-culturaleMuscarinic AntagonistsPersonal SatisfactionSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineHealth careMedicineHumansCOPD management Econometric model Healthcare costs030212 general & internal medicineAdrenergic beta-2 Receptor AgonistsAverage costAgedAged 80 and overCOPDbiologyCOPD management; Econometric model; Healthcare costsbusiness.industryCOPD managementOxygen Inhalation TherapyRegression analysisHealth Care CostsLamaMiddle AgedHealthcare costsbiology.organism_classificationmedicine.diseaseRandom effects modelBronchodilator AgentsPatient Care ManagementRespiratory Function TestsEconometric model030228 respiratory systemItalyEmergency medicinePublic universityDisease ProgressionPatient ComplianceDrug Therapy CombinationbusinessPanel dataFollow-Up Studies
researchProduct

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis

2020

Abstract Background The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and respiratory specialists in the prescription of inhaler devices for asthma patients who initiated inhalation therapy. Methods We retrospectively analysed prescriptions by GPs and respiratory specialists to asthma patients commencing inhaled corticosteroid/long-acting β2-agonist combination therapy available as both pressurised metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs). Patient characteristics were compared by device and multivariate analysis was used to model the likelihood of receiving a pMDI as oppos…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/10 - Malattie Dell'Apparato RespiratorioGeneral practitioner03 medical and health sciencesdry powder inhaler0302 clinical medicineInhalersAdrenal Cortex HormonesAdrenergic beta-2 Receptor AntagonistsAsthma controlGeneral practitionersAdministration InhalationRetrospective analysisMedicine030212 general & internal medicineMetered Dose InhalersMedical prescriptionAsthmaRetrospective Studiesbusiness.industryInhalerdry powder inhalersInhalerOdds ratiomedicine.diseaseConfidence intervalAsthmaPressurised metered-dose inhalerAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialistsPrescriptions030228 respiratory systemRespiratory specialistsInhalationDelayed-Action PreparationsEmergency medicineAdministrationPressurised metered-dose inhalersbusinessAsthma; dry powder inhalers; General practitioners; Inhalers; Pressurised metered-dose inhalers; Respiratory specialists; Administration Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Antagonists; Asthma; Delayed-Action Preparations; Retrospective Studies; Dry Powder Inhalers; Metered Dose Inhalers; Prescriptions
researchProduct

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease

2020

<b><i>Background:</i></b> Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). <b><i>Objectives:</i></b> The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). <b><i>Methods:</i></b> This post hoc analysis of the SAT study included all enrolled …

Pulmonary and Respiratory MedicineMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic ObstructiveHealth BehaviorClinical InvestigationsPulmonary diseaseSocio-culturaleDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Indexchronic obstructive pulmonary diseaseTreatment satisfactionIllness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDiagnostic Self EvaluationInternal medicineSurveys and QuestionnairesPost-hoc analysismedicineSettore MED/10HumansAdherence awareness chronic obstructive pulmonary disease patient-reported outcomesIn patientawarenessPatient Reported Outcome MeasuresAgedCOPDPracticebusiness.industryHealth KnowledgeSelf-Managementmedicine.diseaseSymptom Flare UpAdherence; Awareness; Chronic obstructive pulmonary disease; Patient-reported outcomes; Aged; Female; Health Knowledge Attitudes Practice; Humans; Italy; Male; Patient Reported Outcome Measures; Patient Satisfaction; Severity of Illness Index; Surveys and Questionnaires; Symptom Flare Up; Diagnostic Self Evaluation; Health Behavior; Pulmonary Disease Chronic Obstructive; Self-Management; Treatment Adherence and ComplianceTreatment Adherence and ComplianceItalyPatient SatisfactionAdherencepatient-reported outcomesAttitudesCopd assessment testFemalebusiness
researchProduct

Cost-description and multiple imputation of missing values: theSATisfaction and adherence to COPD treatment(SAT) study

2018

Aim:This article reports on a retrospective quarterly cost description (CD) performed on 401 patients with stable chronic obstructive pulmonary disease (COPD) at enrolment in the national, multicen...

COPDmedicine.medical_specialtymultiple imputationbusiness.industry030503 health policy & servicesHealth PolicySAT studyPulmonary diseasemedicine.diseaseMissing datahumanitiesCOPD Italy SAT study cost description multiple imputation03 medical and health sciences0302 clinical medicineItalyInternal medicinemedicineCOPD030212 general & internal medicine0305 other medical sciencebusinesscost descriptionGlobal & Regional Health Technology Assessment: Italian; Northern Europe and Spanish
researchProduct

The hidden burden of severe asthma: from patient perspective to new opportunities for clinicians

2020

Severe asthma is an important topic in respiratory diseases, due to its high impact on morbidity and mortality as well as on health-care resources. The many challenges that still exist in the management of the most difficult-to-treat forms of the disease, and the acknowledgement of the existence of unexplored areas in the pathophysiological mechanisms and the therapeutic targets represent an opportunity to gather experts in the field with the immediate goals to summarize current understanding about the natural history of severe asthma and to identify gaps in knowledge and research opportunities, with the aim to contribute to improved medical care and health outcomes. This article is a conse…

severe asthmamedicine.medical_specialtySevere asthmaprecision medicineAcknowledgementlcsh:MedicineSocio-culturaleReviewDiseasebiomarkers patient’s perspective precision medicine severe asthma.Medical care03 medical and health sciencesTherapeutic approach0302 clinical medicineMedicine030212 general & internal medicineddc:610Intensive care medicinebusiness.industrylcsh:RPerspective (graphical)General MedicineResearch opportunitiesBiomarkers patient’s perspective precision medicine severe asthmaBiomarkers; Patient’s perspective; Precision medicine; Severe asthmapatient’s perspectiveNatural history030228 respiratory systembusinessBiomarkers
researchProduct

Late Breaking Abstract - Relationship between clinical features and mortality in a cohort of COPD patients

2021

Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease with poor outcomes, including a high mortality. GULP is a multicenter Italian study that described clinical characteristics, exacerbation rates and survival of a cohort of COPD patients, as part of AstraZeneca’s AvoidEX program. Aims and objectives: To evaluate whether the clinical profile of subjects enrolled in the GULP study predicts mortality on a period of 3 years. Methods: Post-hoc analysis of an observational, multicenter, retrospective study. Patients were stratified according to survival status: alive (A) and dead (D). Clinical characteristics, comorbidities and exacerbation rates were reported in the…

COPDmedicine.medical_specialtyExacerbationbusiness.industryRetrospective cohort studyDiseaseOdds ratiomedicine.diseaseInternal medicineHeart failureCohortmedicinebusinessProgressive diseaseMonitoring airway disease
researchProduct

Asthma management in a specialist setting: Results of an Italian Respiratory Society survey.

2017

Abstract Background Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. Aim to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. Method: A quantitative research program was implemented. Data were collected…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyConcordanceSocio-culturalePractice PatternsSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Retrospective StudieSurveys and QuestionnairesSeverity of illnessHealth caremedicineSurveys and QuestionnaireHumansPharmacology (medical)030212 general & internal medicinePractice Patterns Physicians'Adult; Aged; Asthma; Female; Humans; Italy; Male; Middle Aged; Practice Patterns Physicians'; Retrospective Studies; Severity of Illness Index; Surveys and Questionnaires; Quality of Life; SpecializationAsthmaAgedRetrospective StudiesModalitiesPhysicians'business.industryBiochemistry (medical)Retrospective cohort studyMiddle Agedmedicine.diseaseAsthmaPulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)030228 respiratory systemItalyTest scoreFamily medicinePhysical therapyQuality of LifeFemalebusinessHumanSpecializationPulmonary pharmacologytherapeutics
researchProduct

Withdrawal of inhaled corticosteroids in COPD: A meta-analysis

2017

Background Conflicting findings exist on the benefit of withdrawal of inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD). We performed a quantitative synthesis in order to assess real impact of ICS discontinuation in COPD patients. Methods We carried out a meta-analysis via random-effects model on the available clinical evidence to evaluate the effect of ICS discontinuation in COPD. Randomized clinical trials and observational real-life studies investigating the effects of ICS withdrawal on the risk of COPD exacerbation, lung function (forced expiratory volume in 1 s [FEV1]) and quality of life (St. George's Respiratory Questionnaire [SGRQ]) were identified by sear…

Pulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classSocio-culturaleSettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.invention03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineGlucocorticoidQuality of lifeRandomized controlled triallawInhaled corticosteroidForced Expiratory VolumeAdministration InhalationmedicineHumansPharmacology (medical)030212 general & internal medicineIntensive care medicineGlucocorticoidsRandomized Controlled Trials as TopicRespiratory Function TestCOPDInhaled corticosteroidsbusiness.industryChronic obstructive pulmonary diseaseBiochemistry (medical)medicine.diseaseRespiratory Function TestsDiscontinuationrespiratory tract diseasesChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal030228 respiratory systemWithholding TreatmentMeta-analysisRelative riskWithdrawalQuality of LifeCorticosteroidObservational studyChronic obstructive pulmonary disease; Inhaled corticosteroids; Withdrawal; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)businessHuman
researchProduct

Disease awareness in patients with COPD: measurement and extent

2018

Ilaria Baiardini,1 Paola Rogliani,2 Pierachille Santus,3 Angelo G Corsico,4 Marco Contoli,5 Nicola Scichilone,6 Fabiano Di Marco,7 Patrizia Lessi,8 Carla Scognamillo,8 Giorgia Molinengo,9 Fabio Ferri,10 Vincenzo Patella,11 Giuseppe Fiorentino,12 Mauro Carone,13 Fulvio Braido14 1Department of Biomedical Sciences, Humanitas University, Milan, Italy; 2Respiratory Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy; 3Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Milan, Italy; 4Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 5Department of Medical Sciences, University of F…

MaleHealth Knowledge Attitudes PracticeTime Factorspatient satisfactionSettore MED/10 - Malattie dell'Apparato RespiratorioDiseaseSeverity of Illness IndexPulmonary Disease Chronic Obstructive0302 clinical medicineCost of IllnessSurveys and QuestionnairesActivities of Daily Living80 and overawareness030212 general & internal medicineLungIllness BehaviorAged 80 and overPracticeCOPDHealth PolicyHealth KnowledgeGeneral MedicineMiddle AgedItalyFemalePublic HealthPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtySocio-culturaleInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary DiseaseTreatment satisfactionIllness perceptions03 medical and health sciencesNegatively associatedAwareness; COPD; Patient satisfaction; Questionnaire; Activities of Daily Living; Aged; Aged 80 and over; Cost of Illness; Dyspnea; Female; Humans; Illness Behavior; Italy; Lung; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Pulmonary Disease Chronic Obstructive; Reproducibility of Results; Severity of Illness Index; Surveys and Questionnaires; Time Factors; Awareness; Health Knowledge Attitudes Practice; Patient Acceptance of Health CaremedicineHumansCOPDIn patientAgedlcsh:RC705-779business.industryquestionnaireEnvironmental and Occupational HealthPublic Health Environmental and Occupational HealthAwareneReproducibility of Resultslcsh:Diseases of the respiratory systemPatient Acceptance of Health Caremedicine.diseaseCOPD; awareness; patient satisfaction; questionnaireawareness; COPD; patient satisfaction; questionnaire; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational HealthClinical trialDyspnea030228 respiratory systemClinical Trial ReportAttitudesPhysical therapyPatient CompliancePatient awarenessbusiness
researchProduct

Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine

2017

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality worldwide, whose burden is expected to increase in the next decades, because of numerous risk factors, including the aging of the population. COPD is both preventable and treatable by an effective management including risk factor reduction, prevention, assessment, and treatment of acute exacerbations and co-morbidities. The available agents approved for COPD treatment are long-acting or ultra-long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) bronchodilators, as well as inhaled corticosteroids (ICS) in combination with LABAs. ICS use has been restricted only to selected COPD patients by th…

Settore MED/10 - Malattie dell'Apparato RespiratorioAlternative medicineCOPD; drivers; inhaled corticosteroids; prescribing; Pulmonary and Respiratory MedicineCOPD; drivers; inhaled corticosteroids; prescribingAdrenal Cortex HormonePulmonary Disease Chronic Obstructive0302 clinical medicineAdrenal Cortex HormonesDrug Combination030212 general & internal medicinePractice Patterns Physicians'Precision Medicineeducation.field_of_studyCOPDEvidence-Based MedicineprescribingdriversBronchodilator AgentsDrug CombinationsMuscarinic AntagonistPractice Guidelines as TopicGuideline AdherenceHumanAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinemedicine.medical_specialtydriverPopulationSocio-culturaleInhaled corticosteroidsMuscarinic Antagonistsinhaled corticosteroid03 medical and health sciencesAdministration InhalationmedicineHumansCOPDMedical prescriptionRisk factorIntensive care medicineeducationAdrenergic beta-2 Receptor AgonistsBronchodilator AgentPrimary Health Carebusiness.industryPrecision medicinemedicine.disease030228 respiratory systemObservational studyinhaled corticosteroidsbusiness
researchProduct

Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study.

2019

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease. The severity grading systems proposed by the Global initiative for Chronic Obstructive Lung Disease (GOLD) have changed over time. The aim of the study was to evaluate if the different GOLD classifications can capture the complexity of the disease by investigating the distribution of lung function and clinical parameters across the GOLD classification systems. This was an observational, retrospective, multicentre study. COPD patients were stratified according to the GOLD severity grading proposed in the 2007, and to the ABCD assessment tool present in the 2011, and 2017 versions of the initiative. Data from body plethy…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyphenotypeCopd patientsSettore MED/10 - Malattie dell'Apparato RespiratorioVital CapacitySocio-culturalePulmonary diseaseSeverity gradingDiseaseGOLD documentairflow obstructionurologic and male genital diseasesSeverity of Illness IndexPulmonary Disease03 medical and health sciencesLeukocyte CountPulmonary Disease Chronic Obstructive0302 clinical medicineRisk FactorsInternal medicineForced Expiratory VolumemedicineCOPDHumanseosinophil030212 general & internal medicineAgedRetrospective StudiesCOPDbusiness.industryairflow obstruction COPD eosinophil GOLD document phenotypeMiddle Agedmedicine.diseaseObstructive lung diseaserespiratory tract diseasesEosinophils030228 respiratory systemItalyairflow obstruction; COPD; eosinophil; GOLD document; phenotype; Aged; Eosinophils; Female; Forced Expiratory Volume; Humans; Inspiratory Capacity; Italy; Leukocyte Count; Male; Middle Aged; Pulmonary Disease Chronic Obstructive; Retrospective Studies; Risk Factors; Severity of Illness Index; Vital CapacityObservational studyFemalesense organsbusinessCOPD; GOLD document; airflow obstruction; eosinophil; phenotypeInspiratory CapacityCOPD
researchProduct

<p>Day and Night Control of COPD and Role of Pharmacotherapy: A Review</p>

2020

The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients' adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circulation (…

medicine.medical_specialtyCOPDEveningbusiness.industryGeneral MedicineDiseasemedicine.diseaseSleep medicinerespiratory tract diseases03 medical and health sciences0302 clinical medicinePharmacotherapy030228 respiratory systemBronchiolitisInternal medicinemedicine030212 general & internal medicinebusinessDynamic hyperinflationAsthmaInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study

2019

Background: Understanding the level of patients’ satisfaction with treatment and its determinants have the potential to impact therapeutic management and clinical outcome in chronic conditions such as chronic obstructive pulmonary disease (COPD). Methods: A national, multicenter, longitudinal, observational study of COPD from 20 Italian pulmonary centers to explore patients’ satisfaction to treatment [assessed by the Treatment Satisfaction Questionnaire, 9 items (TSQM-9)] and association with clinical parameters [including dyspnea score, COPD Assessment Test (CAT) score, exacerbation rate], adherence to treatment [Morisky Medication-Taking Adherence Scale (MMAS-4)], illness perception [eval…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyCOPD; adherence; treatment satisfactionPulmonary diseaseSocio-culturaleTreatment resultstreatment satisfactionSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome (game theory)Medication AdherencePulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesAdministration InhalationSettore MED/10MedicineHumansCOPDPharmacology (medical)030212 general & internal medicineadherenceIntensive care medicineOriginal ResearchAgedlcsh:RC705-779adherence COPD treatment satisfactionbusiness.industrylcsh:Diseases of the respiratory systemMiddle AgedDyspneaInhalation030228 respiratory systemItalyPatient SatisfactionAdministrationObservational studyFemalebusinessFollow-Up Studies
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: A systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7…

ExacerbationReviewQuinoloneslaw.inventionPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicineRandomized controlled trialsystematic reviewlaw030212 general & internal medicineCOPDLABA LAMA fixed-dose combination COPD systematic reviewbiologyHealth PolicyOlodaterolLAMAGeneral MedicineLamaRespiratory Function Testsfixed-dose combinationDrug CombinationsTreatment OutcomeIndanssystematic review.hormones hormone substitutes and hormone antagonistsmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyFixed-dose combinationLABA; LAMA; fixed-dose combination; COPD; systematic reviewLABAMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesInternal medicinemedicineHumansCOPDAdverse effectAdrenergic beta-2 Receptor Agonistslcsh:RC705-779business.industryPublic Health Environmental and Occupational Healthlcsh:Diseases of the respiratory systemCOPD; LABA; LAMA; fixed-dose combination; systematic reviewmedicine.diseasebiology.organism_classificationGlycopyrrolate030228 respiratory systemchemistryDelayed-Action PreparationsIndacaterolbusiness
researchProduct

Late Breaking Abstract - Validation of a tool for the assessment of disease awareness (DA) in COPD

2017

Background: DA could influence adherence to treatment and outcomes. No validated tools are available to assess DA in COPD Aims: To generate a tool able to explore DA in COPD patients, the Disease Awareness in COPD Questionnaire (DACQ) Methods: A 2-step Delphi approach was used to develop a questionnaire that was tested for validity in a cohort of COPD patients of an Italian observational, multicenter, prospective study (SAT study - NCT02689492) Results: Consensus on a 27-item provisional questionnaire was obtained with 2 Delphi rounds. Factor analysis showed a 4-factor solution accounting for 35% of variance; each factor (disease acceptance, awareness of treatment needs, disease knowledge, …

COPDmedicine.medical_specialtyRasch modelbusiness.industryDelphi methodmedicine.diseaseSpearman's rank correlation coefficientCronbach's alphaCohortmedicinePhysical therapyObservational studybusinessProspective cohort studyEpidemiology
researchProduct

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics

2019

Background: Healthcare decisions made on the basis of insufficient evidence may potentially have ineffective or even harmful consequences. The proportion of older ages (over 65 years) in randomized controlled trials (RCTs) for severe asthma is not enough to establish whether anti-IL-5/IL-5R therapies are equally effective in the elderly as in younger subjects. Methods: In order to assess the relationship between age and the efficacy of anti-IL-5 monoclonal antibodies (mABs) with respect to the risk of exacerbations and changes in FEV1, a meta-regression analysis via random-effect method was carried out by plotting the effect estimates (outcome variables) resulting from the pairwise meta-ana…

Pulmonary and Respiratory Medicinelcsh:Immunologic diseases. AllergymABs monoclonal antibodiesSevere asthmamedicine.medical_specialtyExacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioImmunologyPopulationEosinophilArticlelaw.invention03 medical and health scienceschemistry.chemical_compoundAge0302 clinical medicineReslizumabRandomized controlled triallawInternal medicineImmunology and AllergyMedicine030223 otorhinolaryngologyeducationAsthmaEos eosinophilseducation.field_of_studybusiness.industryyrs yearsAnti-IL5medicine.diseaseBenralizumabEosinophilsRCTs Randomized Controlled TrialsClinical trial030228 respiratory systemchemistryTherapybusinesslcsh:RC581-607Mepolizumabmedicine.drug
researchProduct

Author_Response_1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observat…

2019

Supplemental material, Author_Response_1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Day and Night Control of COPD and Role of Pharmacotherapy: A Review

2020

Abstract The topic of 24-hour management of COPD is related to day-to-night symptoms management, specific follow-up and patients’ adherence to therapy. COPD symptoms strongly vary during day and night, being worse in the night and early morning. This variability is not always adequately considered in the trials. Night-time symptoms are predictive of higher mortality and more frequent exacerbations; therefore, they should be a target of therapy. During night-time, in COPD patients the supine position is responsible for a different thoracic physiology; moreover, during some sleep phases the vagal stimulation determines increased bronchial secretions, increased blood flow in the bronchial circ…

nightLABAReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato Respiratoriocopd – symptoms – dyspnea – night – sleep – follow-up – adherence – circadian lama – laba – icsAdherence; Circadian; COPD; Dyspnea; Follow-up; Night; Sleep; SymptomsPulmonary Disease Chronic ObstructiveAdrenal Cortex HormonesAdministration InhalationSettore MED/10follow-upCOPDHumansadherencesleepAdrenergic beta-2 Receptor Agonistslcsh:RC705-779Circadianlcsh:Diseases of the respiratory systemdyspnearespiratory tract diseasesBronchodilator Agentscircadian LAMAICSsymptomsAdherence Circadian COPD Dyspnea Follow-up Night Sleep SymptomsInternational Journal of COPD
researchProduct

Reviewer_2_v.1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observation…

2019

Supplemental material, Reviewer_2_v.1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

2018

Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Ital…

International Journal of Chronic Obstructive Pulmonary Diseasehormones hormone substitutes and hormone antagonistsInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Contoli_et_al_Additional_file20190924 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a m…

2019

Supplemental material, Contoli_et_al_Additional_file20190924 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Reviewer_1_v.1 – Supplemental material for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observation…

2019

Supplemental material, Reviewer_1_v.1 for Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study by Marco Contoli, Paola Rogliani, Fabiano Di Marco, Fulvio Braido, Angelo G. Corsico, Christian A. Amici, Roberto Piro, Riccardo Sarzani, Patrizia Lessi, Carla Scognamillo, Nicola Scichilone and Pierachille Santus in Therapeutic Advances in Respiratory Disease

110203 Respiratory DiseasesFOS: Clinical medicine111702 Aged Health CareFOS: Health sciences111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct

Supplementary_Material – Supplemental material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD…

2018

Supplemental material, Supplementary_Material for Cost-description and multiple imputation of missing values: the SATisfaction and adherence to COPD treatment (SAT) study by Carlo Lazzaro, Fabiano Di Marco, Nicola Scichilone, Fulvio Braido, Marco Contoli, Paola Rogliani, Pierachille Santus, Valentina Acciai, Carla Scognamillo, Irene Olivi and Angelo Guido Corsico in Global & Regional Health Technology Assessment

111708 Health and Community ServicesFOS: Health sciences
researchProduct